Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.

Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM

Open source

DOI: 10.1016/j.ygyno.2024.09.002
Published: 2024 Nov
Container: Gynecologic oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2024.09.002,
  title = {Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.},
  author = {Brown J and Miller A and Holman LL and Backes F and Nagel C and Bender D and Miller DS and Powell MA and Westin SN and Bonebrake A and Muller CY and Secord AA and Crane E and Schorge J and Tew WP and Sood AK and Bookman MA and Aghajanian C and Gershenson DM},
  year = {2024},
  journal = {Gynecologic oncology},
  doi = {10.1016/j.ygyno.2024.09.002},
  url = {https://doi.org/10.1016/j.ygyno.2024.09.002}
}

RIS

TY  - JOUR
TI  - Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
AU  - Brown J
AU  - Miller A
AU  - Holman LL
AU  - Backes F
AU  - Nagel C
AU  - Bender D
AU  - Miller DS
AU  - Powell MA
AU  - Westin SN
AU  - Bonebrake A
AU  - Muller CY
AU  - Secord AA
AU  - Crane E
AU  - Schorge J
AU  - Tew WP
AU  - Sood AK
AU  - Bookman MA
AU  - Aghajanian C
AU  - Gershenson DM
PY  - 2024
JO  - Gynecologic oncology
DO  - 10.1016/j.ygyno.2024.09.002
UR  - https://doi.org/10.1016/j.ygyno.2024.09.002
ER  -

APA

J, B., A, M., LL, H., F, B., C, N., D, B., DS, M., MA, P., SN, W., A, B., CY, M., AA, S., E, C., J, S., WP, T., AK, S., MA, B., C, A., & DM, G. (2024). Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2024.09.002

Source records

pubmed · retrieved 2026-09-25T16:37:02.577Z